2016
DOI: 10.24265/horizmed.2016.v16n3.03
|View full text |Cite
|
Sign up to set email alerts
|

Estudio de la biodisponibilidad relativa de una formulación multifuente de sulfametoxazol respecto al medicamento referente

Abstract: Andonaire RESUMENObjetivo: Determinar la biodisponibilidad relativa de una formulación multifuente oral de sulfametoxazol de 200 mg/5 ml respecto a la formulación referente en Oryctolagus cuniculus L (conejos albinos). Material y métodos: Las muestras estudiadas consistieron en 25 frascos de suspensión de sulfametoxazol/ trimetoprima multifuente de 200 mg: 40 mg/5 ml asignado con la letra T1 para el lote 11070674; y como referente (R) 25 frascos de suspensión de Bactrim de 200 mg: 40 mg/5 ml, lote RJ0774. El p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 4 publications
0
1
0
Order By: Relevance
“…Dissolution is a kinetic process in which a solid dosage form dissolves in a dissolution medium, thereby releasing the drug within a specific amount of time (1). To demonstrate therapeutic equivalence, it is necessary to do bioequivalence studies in vitro and in vivo (i.e., relative bioavailability, pharmacodynamics, and clinical trials) (3)(4)(5)(6)(7). In vivo studies are performed when there are differences in bioequivalence that indicate a lack of therapeutic equivalence (3,8).…”
Section: Introductionmentioning
confidence: 99%
“…Dissolution is a kinetic process in which a solid dosage form dissolves in a dissolution medium, thereby releasing the drug within a specific amount of time (1). To demonstrate therapeutic equivalence, it is necessary to do bioequivalence studies in vitro and in vivo (i.e., relative bioavailability, pharmacodynamics, and clinical trials) (3)(4)(5)(6)(7). In vivo studies are performed when there are differences in bioequivalence that indicate a lack of therapeutic equivalence (3,8).…”
Section: Introductionmentioning
confidence: 99%